LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | PF431396 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1659 | 4245 | 0.3932 | 0.1128 |
| SK-BR-3 | PF431396 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 1521 | 4245 | 0.3617 | 0.0551 |
| SK-BR-3 | PF431396 | 10 | uM | LJP5 | 72 | hr | 1401 | 1345 | 4245 | 0.3189 | -0.0245 |
| SK-BR-3 | Celastrol | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3226 | 4168 | 0.7743 | 0.6998 |
| SK-BR-3 | Celastrol | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3535 | 4168 | 0.8487 | 0.8001 |
| SK-BR-3 | Celastrol | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1875 | 4168 | 0.4495 | 0.2011 |
| SK-BR-3 | Celastrol | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1280 | 4168 | 0.3068 | -0.0574 |
| SK-BR-3 | Celastrol | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1162 | 4168 | 0.2790 | -0.1123 |
| SK-BR-3 | Celastrol | 10 | uM | LJP6 | 72 | hr | 1401 | 1126 | 4168 | 0.2703 | -0.1301 |
| SK-BR-3 | SU11274 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4495 | 4245 | 1.0566 | 1.0667 |
| SK-BR-3 | SU11274 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4255 | 4245 | 1.0006 | 0.9986 |
| SK-BR-3 | SU11274 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4486 | 4245 | 1.0566 | 1.0702 |
| SK-BR-3 | SU11274 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4034 | 4245 | 0.9491 | 0.9341 |
| SK-BR-3 | SU11274 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3915 | 4245 | 0.9204 | 0.8961 |
| SK-BR-3 | SU11274 | 10 | uM | LJP5 | 72 | hr | 1401 | 1480 | 4245 | 0.3491 | 0.0335 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1885 | 4168 | 0.4520 | 0.2065 |
| SK-BR-3 | Canertinib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1687 | 4168 | 0.4049 | 0.1253 |
| SK-BR-3 | Canertinib | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1608 | 4168 | 0.3864 | 0.0917 |
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1498 | 4168 | 0.3593 | 0.0426 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1395 | 4168 | 0.3346 | -0.0033 |
| SK-BR-3 | Canertinib | 10 | uM | LJP6 | 72 | hr | 1401 | 1094 | 4168 | 0.2621 | -0.1472 |
| SK-BR-3 | NVP-AEW541 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4161 | 4245 | 0.9832 | 0.9810 |
| SK-BR-3 | NVP-AEW541 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4053 | 4245 | 0.9574 | 0.9485 |
| SK-BR-3 | NVP-AEW541 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 3778 | 4245 | 0.8902 | 0.8595 |
| SK-BR-3 | NVP-AEW541 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3922 | 4245 | 0.9230 | 0.9010 |